Calidi Biotherapeutics CLDI Income Statement (2021-2026)

NYSE CLDI
$1.34 -0.01 (-0.72%)
As of: Sep 9, 2026 · 3:59 PM EDT
Reported Financials

Calidi Biotherapeutics Quarterly Income Statement

Periods 18 quarters
Latest Jun 2026

Calidi Biotherapeutics reported net income of -$4.16M for the quarter ended Jun 2026. This income statement covers 18 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot) 0.10M0.10M0.10M0.10M0.10M0.09M0.09M
Research & DevelopmentR&D 1.95M2.26M2.62M3.18M3.25M3.96M2.74M2.17M2.15M1.81M2.42M2.59M2.36M2.36M2.56M
Selling, General & AdministrativeSG&A 5.04M2.42M2.79M3.36M3.97M5.86M4.01M3.60M3.07M2.21M2.64M3.07M2.69M2.11M1.59M
Other Operating ExpensesOther Opex 0.53M0.36M-0.10M-0.10M-0.10M-0.10M-0.10M-0.09M-0.09M
Operating ExpensesOpex 0.53M0.36M6.99M4.69M5.41M6.54M7.22M9.82M6.75M5.77M5.23M4.03M5.06M5.66M5.05M4.47M4.15M
Operating IncomeOp. Inc -0.53M-0.36M-6.99M-4.69M-5.41M-6.54M-7.22M-9.82M-6.75M-5.77M-5.23M-4.03M-5.06M-5.66M-5.05M-4.47M-4.15M
EBIT -0.53M-0.36M-6.99M-4.69M-5.41M-6.54M-7.22M-9.82M-6.75M-5.77M-5.23M-4.03M-5.06M-5.66M-5.05M-4.47M-4.15M
Non-operating items
Non Operating Interest Expenses 0.03M0.10M0.20M0.21M0.30M0.30M0.30M0.17M0.13M0.11M0.04M0.03M0.03M0.04M0.03M
Non Operating Investment IncomeNon-Op. Investment Inc. 0.00M0.03M0.01M
Interest & Investment IncomeInt & Inv Inc 0.02M0.16M1.09M
Other Non Operating IncomeOther Non Op Inc. 0.00M-0.01M-0.01M-0.02M-0.01M-0.02M-0.02M0.01M0.01M0.01M-0.01M-0.02M0.02M0.31M0.03M
Non Operating IncomeNon Op. Inc. 1.99M4.52M1.63M-3.07M-1.04M-5.96M5.21M1.59M-0.47M0.01M0.16M-0.12M0.00M-0.09M-0.12M0.41M-0.01M
Net income details
EBT 1.46M4.16M-5.35M-7.76M-6.46M-12.50M-2.01M-8.23M-7.22M-5.76M-5.07M-4.14M-5.06M-5.76M-5.17M-4.06M-4.16M
Tax ProvisionsTaxes 0.00M-0.00M0.00M0.00M0.01M-0.00M0.00M0.01M-0.00M0.00M0.00M0.00M0.01M-4.23M0.01M
Profit After TaxPAT -7.74M-4.58M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.22M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M-4.06M-4.16M
Income from Non-Controlling InterestsInc. Minority -0.01M-0.05M-0.08M-0.05M-0.03M-0.19M
Income from Continuing OperationsIncome (Continuing) 1.46M4.16M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.22M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M0.17M-4.16M
Consolidated Net IncomeConsol Net Inc. 1.46M4.16M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.22M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M0.17M-4.16M
Income towards Parent CompanyParent Net Inc 1.46M4.16M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.22M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M0.17M-4.16M
Net Income towards Common StockholdersNet Income 1.46M4.16M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.22M-7.44M-5.05M-4.10M-4.99M-5.71M-10.82M-4.06M-4.16M
Additional items
EPS (Basic) 122.06347.38-495.65-842.59-628.05-0.00M-271.57-935.65-390.22-268.05-124.03-98.27-35.34-31.78-35.29-15.09-2.94
EPS (Diluted) 122.06347.38-495.65-842.59-628.05-0.00M-271.57-935.65-390.22-268.05-124.03-98.27-35.34-31.78-35.29-15.09-2.94
Shares Outstanding 0.00M0.01M0.01M0.01M0.01M0.01M0.00M0.01M0.01M0.02M0.03M0.04M0.04M0.14M0.18M0.31M0.27M1.42M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 0.00M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.02M0.03M0.04M0.04M0.14M0.18M0.31M0.27M1.42M
Shares Outstanding (Entity)Shares Outstanding (Entity.) 0.02M0.03M0.03M0.02M0.02M0.01M0.01M0.01M0.01M0.02M0.03M0.05M0.04M0.17M0.18M0.31M0.27M1.42M
EBITDA -0.53M-0.36M-6.99M-4.69M-5.41M-6.54M-7.22M-9.82M-6.75M-5.67M-5.13M-3.93M-5.06M-5.57M-4.94M-4.37M-4.06M
Interest ExpensesInt Expense 0.03M0.10M0.20M0.21M0.30M0.30M0.30M0.17M0.13M0.11M0.04M0.03M0.03M0.04M0.03M
Tax Rate -0.02%0.04%-0.06%-0.03%-0.55%0.04%-0.06%-0.14%0.02%-0.07%-0.06%-0.07%-0.19%104.09%-0.12%